Stem Cells Dev:新研究使肝移植成功率大大增加!

2017-10-15 佚名 medicalxpress

研究人员报道了一种在保留器官的三维结构和细胞外基质(ECM)成分的同时,从整个人肝脏成功地去除细胞物质的方法。他们进一步证明了用人细胞重新喂养这些肝支架的可行性,提供了非破坏性脱细胞方法的概念证明,以生成用于移植的生物工程化肝移植物。该研究发表在干细胞与发育中。

研究人员报道了一种在保留器官的三维结构和细胞外基质(ECM)成分的同时,从整个人肝脏成功地去除细胞物质的方法。他们进一步证明了用人细胞重新喂养这些肝支架的可行性,提供了非破坏性脱细胞方法的概念证明,以生成用于移植的生物工程化肝移植物。该研究发表在干细胞与发育中。

LucvanderLaan,JeroendeJonge以及来自荷兰鹿特丹的伊拉斯姆斯MC大学医学中心的同事共同撰写了题为“使用受控灌注移植器官生物支架的全人肝移植物脱细胞”的文章。他们描述了通过控制机器灌注进行的脱细胞化方案,其使用非生物洗涤剂去除现有的肝细胞,保留完整的ECM,这对于肝支架的成功重新接种和最终的器官再生是至关重要的。研究人员表示,虽然该方案完全消除细胞DNA和RNA,但它留下了对新引入的细胞无毒的生物支架,并保持了原始肝脏微血管和胆汁引流网络的解剖特征。

“终末期肝病患者的可用移植供体缺乏明确需要替代治疗方法,这里的研究人员提出了成功的脱细胞化和随后的肝脏再生的概念证明,”韦恩州立大学医学院总编辑格雷厄姆·帕克博士,卡曼和安·亚当斯说道。

原始出处:

Verstegen Monique M.A, Willemse Jorke, van den Hoek Sjoerd, et.al. Decellularization of Whole Human Liver Grafts Using Controlled Perfusion for Transplantable Organ Bioscaffolds. Stem Cells and Development. September 2017, 26(18): 1304-1315.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2018-03-19 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
    2018-10-01 fzwish20000
  6. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1870214, encodeId=635018e02146c, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Dec 04 14:09:00 CST 2017, time=2017-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960475, encodeId=58d819604e584, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Mar 19 19:09:00 CST 2018, time=2018-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794883, encodeId=b97a1e94883ac, content=<a href='/topic/show?id=46e716e82a6' target=_blank style='color:#2F92EE;'>#stem cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16782, encryptionId=46e716e82a6, topicName=stem cells)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3883266, createdName=yykkxiaodou, createdTime=Sun Oct 29 23:09:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794507, encodeId=c93d1e9450738, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 27 09:09:00 CST 2017, time=2017-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982265, encodeId=03ee1982265fe, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Mon Oct 01 05:09:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482026, encodeId=22ac1482026f9, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614951, encodeId=60f516149512f, content=<a href='/topic/show?id=d74a44e2e7' target=_blank style='color:#2F92EE;'>#cells#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4472, encryptionId=d74a44e2e7, topicName=cells)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=659819575782, createdName=124988c7m101暂无昵称, createdTime=Tue Oct 17 01:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=)]

相关资讯

盘点:肝移植近期重要研究进展一览

肝移植是被全世界认可的治疗终末期肝病的有效手段之一。目前,肝移植在全国范围内已得到广泛开展,这里梅斯小编整理了近期关于肝移植的重要研究进展与大家一同分享。【1】乙肝肝移植术后恩替卡韦单药治疗长期预后慢性乙型肝炎(CHB)的患者肝移植后,长期抗病毒治疗对预防乙肝复发是必须的。研究人员探究了265例未使用乙肝免疫球蛋白(HBIG)恩替卡韦单一药物治疗的乙型肝炎(CHB)肝移植患者的长期预后。结果表明,

J Hepatol:等待肝移植的患者抗病毒治疗的临床效果

总之,研究表明:等待进行肝移植的患者,应用抗病毒治疗是安全、有效的。四分之一的失代偿性肝硬化患者,经抗病毒治疗后,病情改善,可以从等候肝移植名单中划除;大多数患者经抗病毒治疗后,病情似乎较为稳定。如此,去除某些经抗病毒治疗后,病情得到改善患者的等待肝移植机会是一项安全的策略,这可能有利于更迫切需要进行肝移植的患者。

Liver Int:索菲布韦在等待进行肝移植的丙型肝炎患者中的疗效

总之,研究结果表明,对于血清HCV-RNA转为阴性时间少于4周或者直到进行肝移植时仍存在病毒血症的患者,桥接抗病毒治疗可以成为病人的一种选择。即使在晚期失代偿性肝硬化患者中,也可以通过治疗,使病情得到改善,达到消除的状态。

Hepatolog:肥胖和非酒精性脂肪性肝炎相关肝移植患者数量将增加

鉴于人群中肥胖流行趋势,预计因NASH相关肝硬化导致的肝移植将显著增加。需要持续的努力以遏制肥胖的流行,以减少未来NASH相关负担。

Gut:关乎上亿肝病患者,中国研究人员参与发现阻断肝硬化新机制,填补领域空白!

目前来说,肝移植是慢性肝病的最终治疗手段,但是供体短缺又是它的一个阻碍,因此广大患者极其迫切地需要能控制甚至逆转肝纤维化的药物。不过,发表在胃肠肝病学顶级期刊《Gut》上的研究成果也许将填补这一“空白”,一组研究人员发现了一个重要靶点的作用机制,抑制它可以阻止甚至逆转肝纤维化

Hepatology:肝细胞癌患者的肝移植治疗——系统评价

等待肝移植的肝细胞癌患者(HCC)经常在等待期间进行治疗,其中包括局部区域治疗(LRT),其目的是预防HCC的进展或减少HCC的疾病负荷,以此获得分配优先级的增加。近期,一项发表在杂志Hepatology上的研究综合了关于LRT在等候肝移植的HCC患者管理中的有效性的证据。研究者们从1996年到2016年4月25日对多个数据库进行了全面搜索,研究招募成年人等待肝移植的肝硬化患者,并在肝移植前使用桥